Related Experiment Video

Updated: Aug 14, 2025

A Simple Pit Assay Protocol to Visualize and Quantify Osteoclastic Resorption In Vitro
07:03

A Simple Pit Assay Protocol to Visualize and Quantify Osteoclastic Resorption In Vitro

Published on: June 16, 2022

6.4K

PD0325901, an ERK inhibitor, attenuates RANKL-induced osteoclast formation and mitigates cartilage inflammation by

Ting Jiang1, Yuhang Gong1, Wekang Zhang1

  • 1Department of Orthopedics, Taizhou Hospital Affiliated to Wenzhou Medical University, Linhai, Zhejiang, China; Bone Development and Metabolism Research Center of Taizhou Hospital of Zhejiang Province, Linhai, Zhejiang, China.

Bioorganic Chemistry
|January 15, 2023
PubMed

Insights

PD0325901, an ERK inhibitor, effectively inhibits osteoclast differentiation and reduces cartilage degeneration in osteoarthritis models. This compound shows promise as a novel therapeutic agent for osteoarthritis treatment.

Area of Science:

  • Biomedical research
  • Pharmacology
  • Osteoarthritis research

Background:

  • Osteoarthritis (OA) involves joint degradation, cartilage injury, and subchondral bone changes.
  • Early intervention in subchondral bone loss can improve OA prognosis.
  • ERK pathway inhibition is a potential therapeutic strategy for OA.

Purpose of the Study:

  • To investigate the therapeutic potential of PD0325901, an ERK inhibitor, in osteoarthritis.
  • To evaluate the effects of PD0325901 on osteoclast differentiation and chondrocyte protection.
  • To assess the efficacy of PD0325901 in an animal model of osteoarthritis.

Main Methods:

  • In vitro studies using bone marrow monocytes/macrophages (BMMs) and ATDC5 cells.
  • Assessment of osteoclast differentiation markers (c-Fos, NFATc1) and pyroptosis levels.
  • In vivo studies using a destabilization of the medial meniscus (DMM) mouse model.

Main Results:

  • PD0325901 inhibited RANKL-induced osteoclast differentiation in a time- and dose-dependent manner.
  • PD0325901 protected ATDC5 cells from IL-1β-induced damage.
  • PD0325901 treatment significantly reduced osteochondral pathological changes and pyroptosis in OA mouse models.

Conclusions:

  • PD0325901 demonstrates significant therapeutic potential for osteoarthritis.
  • The ERK inhibitor PD0325901 effectively mitigates key pathological features of OA.
  • PD0325901 represents a promising new therapeutic candidate for osteoarthritis treatment.
Keywords:
CartilageIL-1βOsteoarthritisOsteoclastsPD0325901

More Related Videos

Differentiation of Functional Osteoclasts from Human Peripheral Blood CD14+ Monocytes11:52

Differentiation of Functional Osteoclasts from Human Peripheral Blood CD14+ Monocytes

Published on: January 27, 2023

3.4K
A RANKL-based Osteoclast Culture Assay of Mouse Bone Marrow to Investigate the Role of mTORC1 in Osteoclast Formation09:37

A RANKL-based Osteoclast Culture Assay of Mouse Bone Marrow to Investigate the Role of mTORC1 in Osteoclast Formation

Published on: March 15, 2018

13.3K

Related Concept Videos

NF-κB-dependent Signaling Pathway02:26

NF-κB-dependent Signaling Pathway

The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The...
7.8K
Osteoclasts in Bone Remodeling01:31

Osteoclasts in Bone Remodeling

Osteoclasts are cells responsible for bone resorption and remodeling. They originate from hematopoietic progenitor cells present in the bone marrow. Numerous progenitor cells fuse to form multinucleated cells, each with 10-20 nuclei. A single osteoclast has a diameter of 150 to 200 µM. These cells have ruffled borders that break down the underlying bone tissue and release minerals such as calcium into the blood in bone resorption. Osteoclasts cling to bones with their ruffled edges during...
3.1K
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
5.8K
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
9.1K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
210
Regulation of the Unfolded Protein Response01:31

Regulation of the Unfolded Protein Response

Inositol-requiring kinase one or IRE1 is the most conserved eukaryotic unfolded protein response (UPR) receptor. It is a type I transmembrane protein kinase receptor with a distinctive site-specific RNase activity. As the binding mechanics of the misfolded proteins with the N-terminal domain of IRE-1 are unclear, three binding models — direct, indirect, and allosteric -- are proposed for receptor activation. Nevertheless, it is known that once a misfolded protein associates with IRE1, it...
2.5K